632 related articles for article (PubMed ID: 9787370)
41. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
42. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
43. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
[TBL] [Abstract][Full Text] [Related]
44. Systemic beta-blocker therapy and brimonidine and timolol.
Coulibaly R
Ophthalmology; 2001 Aug; 108(8):1368. PubMed ID: 11470677
[No Abstract] [Full Text] [Related]
45. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
[TBL] [Abstract][Full Text] [Related]
46. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
47. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
48. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
49. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
Camras CB
Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
51. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
[TBL] [Abstract][Full Text] [Related]
52. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
[TBL] [Abstract][Full Text] [Related]
53. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
Motolko MA
Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444
[TBL] [Abstract][Full Text] [Related]
54. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
55. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials.
Zabriskie N; Netland PA;
Adv Ther; 2003; 20(2):92-100. PubMed ID: 12836809
[TBL] [Abstract][Full Text] [Related]
56. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
57. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany.
Thelen U; Buchholz P; Kimmich F
Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517
[TBL] [Abstract][Full Text] [Related]
58. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
59. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Cantor LB; Safyan E; Liu CC; Batoosingh AL
Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052
[TBL] [Abstract][Full Text] [Related]
60. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
